StockMacro
Menu

TransCode Therapeutics

$1.16 -78% in 6 monthsMarket cap $20.1M

RNAZ on XNAS, Health Care, TransCode Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 86% in 12 months to $1.16 as a $145.4M net loss dwarfs $4.6M of cash.

  • BadNet cash just $1.5M after $3.1M of debt

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

Industry
Pharmaceutical preparations (Health Care)
Employees
12
Website
transcodetherapeutics.com
Listed
Nasdaq, US
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $107.4M.
Quarter to 31 Dec 2021: revenue –, net income -$2.8MQuarter to 31 Mar 2022: revenue –, net income -$3.5MQuarter to 30 Jun 2022: revenue –, net income -$4.7MQuarter to 30 Sep 2022: revenue –, net income -$4.3MQuarter to 31 Dec 2022: revenue –, net income -$5.1MQuarter to 31 Mar 2023: revenue –, net income -$4.8MQuarter to 30 Jun 2023: revenue –, net income -$4.3MQuarter to 30 Sep 2023: revenue –, net income -$5.3MQuarter to 31 Dec 2023: revenue –, net income -$4.1MQuarter to 31 Mar 2024: revenue –, net income -$3.3MQuarter to 30 Jun 2024: revenue –, net income -$5.2MQuarter to 30 Sep 2024: revenue –, net income -$2.3MQuarter to 31 Dec 2024: revenue –, net income -$5.9MQuarter to 31 Mar 2025: revenue –, net income -$12.1MQuarter to 30 Jun 2025: revenue –, net income -$4.3MQuarter to 30 Sep 2025: revenue –, net income -$4.9MQuarter to 31 Dec 2025: revenue –, net income -$13.4MQuarter to 31 Mar 2026: revenue –, net income -$17.8MQuarter to 30 Jun 2026: revenue –, net income -$6.8MQuarter to 30 Sep 2026: revenue –, net income -$107.4M
31 Dec 2021RevenueNet incomeNet losstallest bar $107.4M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$107.4M
30 Jun 2026–-$6.8M
31 Mar 2026–-$17.8M
31 Dec 2025–-$13.4M
30 Sep 2025–-$4.9M
30 Jun 2025–-$4.3M
31 Mar 2025–-$12.1M
31 Dec 2024–-$5.9M
30 Sep 2024–-$2.3M
30 Jun 2024–-$5.2M
31 Mar 2024–-$3.3M
31 Dec 2023–-$4.1M
30 Sep 2023–-$5.3M
30 Jun 2023–-$4.3M
31 Mar 2023–-$4.8M
31 Dec 2022–-$5.1M
30 Sep 2022–-$4.3M
30 Jun 2022–-$4.7M
31 Mar 2022–-$3.5M
31 Dec 2021–-$2.8M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$145.4M -$27.1M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$9.29 -$570.10
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -866% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $4.6M $2.8M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $3.1M –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$1.5M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.10 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.86
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.62 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
TransCode TherapeuticsRNAZ (this company) $20.1Mloss–––
Adicet BioACET $20.0Mloss–––
Aardvark TherapeuticsAARD $20.2Mloss–––
TherapeuticsMDTXMD $19.8M1625.3+34%3.3%
IGC PharmaIGC $19.6Mloss15.6+14%-644%
Edesa BiotechEDSA $19.3Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

–

No data for this company

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

0.6%

100K shares held by 13F filers (30 Sep 2026) of 17.3M outstanding (12 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.3%

52K shares sold short (30 Oct 2026) of 17.3M outstanding (12 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

2.0

52K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-5.4%

55K shares sold short in the report before, 52K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

30%

30% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 43%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

8

8 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

8 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $1.16 on 20 Nov 2026, -86% over 12 months (12-month range $1.16 to $12.34)

  • Sharp change
  • 8-K and other filings
  • Federal award
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
Capital spending per quarter. Capital spending $500 in the latest quarter.
Institutional holders (13F filers). 12 13F filers reported holding it in the latest 13F quarter, +50% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months, -100% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
11 Sep 20268-K and other filingsDirector or officer change
11 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 May 20268-K and other filingsDelisting notice or listing transfer
1 May 20268-K and other filingsRegistered new securities for sale (S-1)
31 Mar 20268-K and other filingsReport will be filed late
22 Dec 20258-K and other filingsDirector or officer change
8 Oct 20258-K and other filingsCompleted an acquisition or asset sale
8 Oct 20258-K and other filingsDirector or officer change
8 Oct 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 May 20258-K and other filingsDelisting notice or listing transfer
15 Apr 2025Sharp changeShort interest spike: short interest spike, 2.6M vs usual 247K (2025-03-31); 63.9x the same period a year earlier
31 Mar 20258-K and other filingsReport will be filed late
12 Dec 20248-K and other filingsPrivate placement of securities (Form D)
6 Dec 20248-K and other filingsRegistered new securities for sale (S-1)
6 Nov 20248-K and other filingsDelisting notice or listing transfer
15 Oct 2024Sharp changeShort interest spike: short interest spike, 1.4M vs usual 250K (2024-09-30); 19.0x the same period a year earlier
5 Oct 2024Federal awardnew Department of Health and Human Services grant R44CA295173 ($1.0M)
5 Oct 2024Sharp changeFirst federal award: first federal award: TRANSCODE THERAPEUTICS, INC.: new Department of Health and Human Services grant R44CA295173 ($1,011,207)
27 Sep 20248-K and other filingsDelisting notice or listing transfer
16 Aug 20248-K and other filingsDelisting notice or listing transfer
13 Aug 2024Sharp changeShort interest spike: short interest spike, 1.6M vs usual 174K (2024-07-31); 111.4x the same period a year earlier
18 Jun 2024Sharp changeShort interest spike: short interest spike, 1.0M vs usual 138K (2024-05-31); 37.5x the same period a year earlier
10 May 20248-K and other filingsDelisting notice or listing transfer
18 Jan 20248-K and other filingsRegistered new securities for sale (S-1)
17 Jan 20248-K and other filingsRegistered new securities for sale (S-1)
16 Jan 20248-K and other filingsDirector or officer change
16 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Jan 20248-K and other filingsRegistered new securities for sale (S-1)
14 Nov 2023Sharp changeShort interest spike: short interest spike, 1.3M vs usual 209K (2023-10-31); 6.0x the same period a year earlier
9 Nov 20238-K and other filingsDelisting notice or listing transfer
27 Oct 20238-K and other filingsDelisting notice or listing transfer
23 Sep 20238-K and other filingsRegistered new securities for sale (S-1)
9 Sep 20238-K and other filingsRegistered new securities for sale (S-1)
29 Aug 20238-K and other filingsRegistered new securities for sale (S-1)
4 Aug 20238-K and other filingsDelisting notice or listing transfer
28 Jul 20238-K and other filingsDelisting notice or listing transfer
8 Jun 20238-K and other filingsDelisting notice or listing transfer
6 Jun 20238-K and other filingsRegistered new securities for sale (S-1)
5 Jun 20238-K and other filingsRegistered new securities for sale (S-1)
19 May 20238-K and other filingsDirector or officer change
19 May 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 May 20238-K and other filingsRegistered new securities for sale (S-1)
18 May 20238-K and other filingsDelisting notice or listing transfer
16 May 2023Sharp changeShort interest spike: short interest spike, 653K vs usual 38K (2023-04-28); 14.0x the same period a year earlier
2 May 2023Sharp changeShort interest spike: short interest spike, 636K vs usual 37K (2023-04-14); 25.7x the same period a year earlier
14 Mar 2023Sharp changeShort interest spike: short interest spike, 541K vs usual 34K (2023-02-28); 10.3x the same period a year earlier
28 Feb 2023Sharp changeShort interest spike: short interest spike, 948K vs usual 34K (2023-02-15); 11.2x the same period a year earlier
1 Feb 20238-K and other filingsRegistered new securities for sale (S-1)
17 Jan 2023Sharp changeShort interest spike: short interest spike, 814K vs usual 34K (2022-12-30); 9.7x the same period a year earlier
3 Jan 2023Sharp changeShort interest spike: short interest spike, 1.1M vs usual 33K (2022-12-15); 12.5x the same period a year earlier
9 Dec 20228-K and other filingsDelisting notice or listing transfer
30 Nov 20228-K and other filingsRegistered new securities for sale (S-1)
28 Nov 20228-K and other filingsRegistered new securities for sale (S-1)
Insider net buying (open market)
Month from 1 Jun 2022: $70K published
Month from 1 Sep 2022: $23K published
Month from 1 Jun 2023: $101K published
Month from 1 Oct 2023: $75K published
Capital spending per quarter
Quarter ended 31 Mar 2021: $75K; public on 17 May 2022
Quarter ended 31 Dec 2021: $86K; public on 1 Apr 2022
Quarter ended 31 Mar 2022: $31K, -59% on a year earlier; public on 17 May 2022
Quarter ended 30 Jun 2022: $42K, +89% on a year earlier; public on 16 Aug 2022
Quarter ended 31 Dec 2022: $28K, -67% on a year earlier; public on 1 Apr 2023
Quarter ended 31 Mar 2023: $13K, -58% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $18K, -57% on a year earlier; public on 15 Aug 2023
Quarter ended 30 Sep 2023: $5K; public on 15 Nov 2023
Quarter ended 31 Mar 2024: $4K, -70% on a year earlier; public on 16 May 2024
Quarter ended 30 Jun 2024: $5K, -75% on a year earlier; public on 15 Aug 2024
Quarter ended 30 Sep 2024: $13K, +179% on a year earlier; public on 15 Nov 2024
Quarter ended 31 Dec 2024: $500; public on 16 Apr 2025
Institutional holders (13F filers)
31 Dec 2021 report: 15; public on 14 Feb 2022
31 Mar 2022 report: 13; public on 16 May 2022
30 Jun 2022 report: 13; public on 15 Aug 2022
30 Sep 2022 report: 12; public on 14 Nov 2022
31 Dec 2022 report: 16; public on 14 Feb 2023
31 Mar 2023 report: 10; public on 15 May 2023
30 Jun 2023 report: 4; public on 14 Aug 2023
30 Sep 2023 report: 10; public on 14 Nov 2023
31 Dec 2023 report: 14; public on 14 Feb 2024
31 Mar 2024 report: 6; public on 15 May 2024
30 Jun 2024 report: 14; public on 14 Aug 2024
30 Sep 2024 report: 8; public on 14 Nov 2024
31 Dec 2024 report: 4; public on 14 Feb 2025
31 Mar 2025 report: 16; public on 15 May 2025
30 Jun 2025 report: 7; public on 14 Aug 2025
30 Sep 2025 report: 8; public on 14 Nov 2025
31 Dec 2025 report: 6; public on 17 Feb 2026
31 Mar 2026 report: 8; public on 15 May 2026
30 Jun 2026 report: 9; public on 14 Aug 2026
30 Sep 2026 report: 12; public on 16 Nov 2026
Federal obligations
Month from 1 Jul 2022: $1.1M published
Month from 1 Nov 2022: $0 published
Month from 1 May 2023: $871K published
Month from 1 Oct 2024: $1.0M published
Month from 1 Jul 2025: $989K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is operating income, quarter at -$109.7M (30 Sep 2026), 2172% below its normal quarter of -$4.8M; higher than 4% of its own history.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
  • Capital spending per quarter: Capital spending $500 in the latest quarter.
  • Institutional holders (13F filers): 12 13F filers reported holding it in the latest 13F quarter, +50% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 8 insider trades

No trades in the last 90 days; the latest was filed 2 Oct 2023. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
2 Oct 2023Thomas A FitzgeraldChief Financial OfficerBuy49,350$0.51$25KForm 4
2 Oct 2023Robert Michael DudleyChief Executive OfficerBuy98,000$0.51$50KForm 4
22 Jun 2023Robert Michael DudleyChief Executive OfficerBuy18,607$2.61$49KForm 4
13 Jun 2023Robert Michael DudleyChief Executive OfficerBuy19,000$2.76$52KForm 4
16 Sep 2022Robert Michael DudleyChief Executive OfficerBuy20,000$1.15$23KForm 4
17 Jun 2022Thomas A FitzgeraldChief Financial OfficerBuy12,000$1.27$15KForm 4
1 Jun 2022Robert Michael DudleyChief Executive OfficerBuy30,000$1.84$55KForm 4

12 institutions reported shares at the end of Q3 2026, 1% of the shares outstanding; 4 opened a position, 1 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Yorkville Advisors Global, LP76K0.44%$127K+56K+286%
Citadel Advisors LLC10K0.06%$17KNew+10K
Vanguard Capital Management LLC6,5450.04%$11KNo change
Vanguard Fiduciary Trust Co2,9820.02%$5KNo change
UBS Group AG2,6500.02%$4K-238-8.2%
Tower Research Capital LLC (TRC)1,7460.01%$3K+1,069+158%
Osaic Holdings, Inc.2700.00%$453New+270
Robinhood Markets, Inc.1020.00%$168
Wells Fargo & Company550.00%$92No change
SBI Securities Co., Ltd.120.00%$20No change

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 4 Sep 2024. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
4 Sep 2024Department of Health and Human ServicesNational Institutes of Health$2.0MPHASE I CLINICAL TESTING OF A FIRST-IN-CLASS THERAPY AGAINST METASTATIC CANCER - SUMMARY METASTATIC DISEASE IS RESPONSIBLE FOR ~90% OF CANCER DEATHS AND IS THE PRIMARY DETERMINANT IN THE LIFE-LIMITING ASPECT OF CANCER. ONE VALIDATED DRIVER OF METASTASIS IS MIRNA-10B, A NON-CODING RNA ASSOCIATED WITH METASTATIC PROGRESSION IN NUMEROUS PRECLINICAL AND > 100 CLINICAL STUDIES. TRANSCODE HAS DEVELOPED A NOVEL THERAPEUTIC AGENT (TERMED MN-ANTI-MIR10B AND COMMERCIALLY DEVELOPED AS TTX-MC138) THAT RELIEGrantUSAspending

Company events

All 54 company events

In 12 months: 2 director or officer changes, 2 major agreements, 1 late report, 1 share registration. Results releases and routine reports are left out.

FiledWhat happenedSource
1 Oct 2026Signed a major agreementSame filing: a debt came due early8-K
11 Sep 2026Director or officer change8-K
22 May 2026Delisting notice or listing transfer8-K
30 Apr 2026Registered new securities for sale (S-1)S-1
7 Apr 2026Signed a major agreementSame filing: took on new debt, sold shares privately8-K
31 Mar 2026Annual report will be filed lateNT 10-K
22 Dec 2025Director or officer change8-K
8 Oct 2025Director or officer change; Signed a major agreement; Completed an acquisition or asset saleSame filing: sold shares privately, changed shareholder rights, changed its bylaws or fiscal year8-K

The 5 newest of 46 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

15 Oct 2024confirmed

Confirmed across sources Government contracts and Short interest and volume

TransCode Therapeutics (RNAZ): won its first federal award in our data, a $1.0M Department of Health and Human Services grant, while it had 1.4M shares sold short in the 30 Sep 2024 report, 19× the same report last year. Two unrelated kinds of activity within 10 days.

  • Government contracts: First federal award, became public on 5 Oct 2024
  • Short interest and volume: Short interest spike, became public on 10 Oct 2024
2023-09-29: 73K2023-10-13: 199K2023-10-31: 1.3M2023-11-15: 483K2023-11-30: 637K2023-12-15: 438K2023-12-29: 405K2024-01-12: 394K2024-01-31: 755K2024-02-15: 221K2024-02-29: 102K2024-03-15: 175K2024-03-28: 40K2024-04-15: 19K2024-04-30: 150K2024-05-15: 174K2024-05-31: 1.0M2024-06-14: 448K2024-06-28: 167K2024-07-15: 25K2024-07-31: 1.6M2024-08-15: 176K2024-08-30: 279K2024-09-13: 905K2024-09-30: 1.4M
The 30 Sep 2024 report against the 24 reports before it. this reportearliernormal: 250K
See the evidence (2 changes)

Government contracts: First federal award became public on 5 Oct 2024

TransCode Therapeutics won its first federal award in our data, a $1.0M Department of Health and Human Services grant.

Source coverage starts
7 Oct 2007
Earlier events of other kinds
0

"First" means first in our data: it fires only when the source's history began at least 365 days earlier.

Short interest and volume: Short interest spike became public on 10 Oct 2024

TransCode Therapeutics had 1.4M shares sold short in the 30 Sep 2024 report, 19× the same report last year.

This period
1.4M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
250K
Typical spread (median absolute deviation)
182K
How far from its usual level
+4.2
Same report last year
73K
History used
1,173 days
2023-09-29: 73K2023-10-13: 199K2023-10-31: 1.3M2023-11-15: 483K2023-11-30: 637K2023-12-15: 438K2023-12-29: 405K2024-01-12: 394K2024-01-31: 755K2024-02-15: 221K2024-02-29: 102K2024-03-15: 175K2024-03-28: 40K2024-04-15: 19K2024-04-30: 150K2024-05-15: 174K2024-05-31: 1.0M2024-06-14: 448K2024-06-28: 167K2024-07-15: 25K2024-07-31: 1.6M2024-08-15: 176K2024-08-30: 279K2024-09-13: 905K2024-09-30: 1.4M
the 30 Sep 2024 report24 earlier reportsnormal: 250K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 11 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 11 Sep 2026Filings record

    Director or officer change

  3. 22 May 2026Filings record

    Delisting notice or listing transfer

  4. 1 May 2026Filings record

    Registered new securities for sale (S-1) (dated 30 Apr 2026)

  5. 31 Mar 2026Filings record

    Report will be filed late

  6. 22 Dec 2025Filings record

    Director or officer change

  7. 8 Oct 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 8 Oct 2025Filings record

    Director or officer change

  9. 8 Oct 2025Filings record

    Completed an acquisition or asset sale

  10. 7 May 2025Filings record

    Delisting notice or listing transfer

  11. 10 Apr 2025Short interest and volume change

    had 2.6M shares sold short in the 31 Mar 2025 report, 64× the same report last year.

    Same report last year: 40K; its normal report is 247K.

    See the evidence
    This period
    2.6M (the 31 Mar 2025 report)
    Normal report (median of 24 earlier)
    247K
    Typical spread (median absolute deviation)
    198K
    How far from its usual level
    +7.9
    Same report last year
    40K
    History used
    1,355 days
    2024-03-28: 40K2024-04-15: 19K2024-04-30: 150K2024-05-15: 174K2024-05-31: 1.0M2024-06-14: 448K2024-06-28: 167K2024-07-15: 25K2024-07-31: 1.6M2024-08-15: 176K2024-08-30: 279K2024-09-13: 905K2024-09-30: 1.4M2024-10-15: 1.2M2024-10-31: 744K2024-11-15: 216K2024-11-29: 606K2024-12-13: 52K2024-12-31: 90K2025-01-15: 81K2025-01-31: 368K2025-02-14: 163K2025-02-28: 541K2025-03-14: 340K2025-03-31: 2.6M
    the 31 Mar 2025 report24 earlier reportsnormal: 247K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 31 Mar 2025Filings record

    Report will be filed late

  13. 12 Dec 2024Filings record

    Private placement of securities (Form D)

  14. 6 Dec 2024Filings record

    Registered new securities for sale (S-1)

  15. 6 Nov 2024Filings record

    Delisting notice or listing transfer

  16. 15 Oct 2024several at once

    won its first federal award in our data, a $1.0M Department of Health and Human Services grant, while it had 1.4M shares sold short in the 30 Sep 2024 report, 19× the same report last year. Two unrelated kinds of activity within 10 days.

    See the evidence (2 changes)

    Government contracts: First federal award became public on 5 Oct 2024

    TransCode Therapeutics won its first federal award in our data, a $1.0M Department of Health and Human Services grant.

    Source coverage starts
    7 Oct 2007
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

    Short interest and volume: Short interest spike became public on 10 Oct 2024

    TransCode Therapeutics had 1.4M shares sold short in the 30 Sep 2024 report, 19× the same report last year.

    This period
    1.4M (the 30 Sep 2024 report)
    Normal report (median of 24 earlier)
    250K
    Typical spread (median absolute deviation)
    182K
    How far from its usual level
    +4.2
    Same report last year
    73K
    History used
    1,173 days
    2023-09-29: 73K2023-10-13: 199K2023-10-31: 1.3M2023-11-15: 483K2023-11-30: 637K2023-12-15: 438K2023-12-29: 405K2024-01-12: 394K2024-01-31: 755K2024-02-15: 221K2024-02-29: 102K2024-03-15: 175K2024-03-28: 40K2024-04-15: 19K2024-04-30: 150K2024-05-15: 174K2024-05-31: 1.0M2024-06-14: 448K2024-06-28: 167K2024-07-15: 25K2024-07-31: 1.6M2024-08-15: 176K2024-08-30: 279K2024-09-13: 905K2024-09-30: 1.4M
    the 30 Sep 2024 report24 earlier reportsnormal: 250K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  17. 10 Oct 2024Short interest and volume change

    had 1.4M shares sold short in the 30 Sep 2024 report, 19× the same report last year.

    Same report last year: 73K; its normal report is 250K.

    See the evidence
    This period
    1.4M (the 30 Sep 2024 report)
    Normal report (median of 24 earlier)
    250K
    Typical spread (median absolute deviation)
    182K
    How far from its usual level
    +4.2
    Same report last year
    73K
    History used
    1,173 days
    2023-09-29: 73K2023-10-13: 199K2023-10-31: 1.3M2023-11-15: 483K2023-11-30: 637K2023-12-15: 438K2023-12-29: 405K2024-01-12: 394K2024-01-31: 755K2024-02-15: 221K2024-02-29: 102K2024-03-15: 175K2024-03-28: 40K2024-04-15: 19K2024-04-30: 150K2024-05-15: 174K2024-05-31: 1.0M2024-06-14: 448K2024-06-28: 167K2024-07-15: 25K2024-07-31: 1.6M2024-08-15: 176K2024-08-30: 279K2024-09-13: 905K2024-09-30: 1.4M
    the 30 Sep 2024 report24 earlier reportsnormal: 250K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 5 Oct 2024Government contracts change

    won its first federal award in our data, a $1.0M Department of Health and Human Services grant.

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2007
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  19. 5 Oct 2024Government contracts record

    TRANSCODE THERAPEUTICS, INC.: new Department of Health and Human Services grant R44CA295173 ($1.0M) (dated 4 Sep 2024)

  20. 27 Sep 2024Filings record

    Delisting notice or listing transfer

  21. 16 Aug 2024Filings record

    Delisting notice or listing transfer

  22. 10 Aug 2024Short interest and volume change

    had 1.6M shares sold short in the 31 Jul 2024 report, 111× the same report last year.

    Same report last year: 15K; its normal report is 174K.

    See the evidence
    This period
    1.6M (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    174K
    Typical spread (median absolute deviation)
    153K
    How far from its usual level
    +6.4
    Same report last year
    15K
    History used
    1,112 days
    2023-07-31: 15K2023-08-15: 1,7942023-08-31: 24K2023-09-15: 126K2023-09-29: 73K2023-10-13: 199K2023-10-31: 1.3M2023-11-15: 483K2023-11-30: 637K2023-12-15: 438K2023-12-29: 405K2024-01-12: 394K2024-01-31: 755K2024-02-15: 221K2024-02-29: 102K2024-03-15: 175K2024-03-28: 40K2024-04-15: 19K2024-04-30: 150K2024-05-15: 174K2024-05-31: 1.0M2024-06-14: 448K2024-06-28: 167K2024-07-15: 25K2024-07-31: 1.6M
    the 31 Jul 2024 report24 earlier reportsnormal: 174K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 12 Jun 2024Short interest and volume change

    had 1.0M shares sold short in the 31 May 2024 report, 37× the same report last year.

    Same report last year: 27K; its normal report is 138K.

    See the evidence
    This period
    1.0M (the 31 May 2024 report)
    Normal report (median of 24 earlier)
    138K
    Typical spread (median absolute deviation)
    104K
    How far from its usual level
    +5.7
    Same report last year
    27K
    History used
    1,051 days
    2023-05-31: 27K2023-06-15: 49K2023-06-30: 56K2023-07-14: 101K2023-07-31: 15K2023-08-15: 1,7942023-08-31: 24K2023-09-15: 126K2023-09-29: 73K2023-10-13: 199K2023-10-31: 1.3M2023-11-15: 483K2023-11-30: 637K2023-12-15: 438K2023-12-29: 405K2024-01-12: 394K2024-01-31: 755K2024-02-15: 221K2024-02-29: 102K2024-03-15: 175K2024-03-28: 40K2024-04-15: 19K2024-04-30: 150K2024-05-15: 174K2024-05-31: 1.0M
    the 31 May 2024 report24 earlier reportsnormal: 138K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 10 May 2024Filings record

    Delisting notice or listing transfer

  25. 18 Jan 2024Filings record

    Registered new securities for sale (S-1)

  26. 17 Jan 2024Filings record

    Registered new securities for sale (S-1)

  27. 16 Jan 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  28. 16 Jan 2024Filings record

    Director or officer change

  29. 11 Jan 2024Filings record

    Registered new securities for sale (S-1)

  30. 10 Nov 2023Short interest and volume change

    had 1.3M shares sold short in the 31 Oct 2023 report, 6.0× the same report last year.

    Same report last year: 219K; its normal report is 209K.

    See the evidence
    This period
    1.3M (the 31 Oct 2023 report)
    Normal report (median of 24 earlier)
    209K
    Typical spread (median absolute deviation)
    190K
    How far from its usual level
    +4.0
    Same report last year
    219K
    History used
    838 days
    2022-10-31: 219K2022-11-15: 7,5652022-11-30: 36K2022-12-15: 1.1M2022-12-30: 814K2023-01-13: 460K2023-01-31: 464K2023-02-15: 948K2023-02-28: 541K2023-03-15: 263K2023-03-31: 319K2023-04-14: 636K2023-04-28: 653K2023-05-15: 443K2023-05-31: 27K2023-06-15: 49K2023-06-30: 56K2023-07-14: 101K2023-07-31: 15K2023-08-15: 1,7942023-08-31: 24K2023-09-15: 126K2023-09-29: 73K2023-10-13: 199K2023-10-31: 1.3M
    the 31 Oct 2023 report24 earlier reportsnormal: 209K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 9 Nov 2023Filings record

    Delisting notice or listing transfer

  32. 27 Oct 2023Filings record

    Delisting notice or listing transfer

  33. 3 Oct 2023Insiders record

    Fitzgerald Thomas A (Chief Financial Officer) bought 49,350 shares of RNAZ ($25,168) (dated 2 Oct 2023)

  34. 3 Oct 2023Insiders record

    Dudley Robert Michael (Chief Executive Officer) bought 98,000 shares of RNAZ ($49,980) (dated 2 Oct 2023)

  35. 23 Sep 2023Filings record

    Registered new securities for sale (S-1) (dated 22 Sep 2023)

  36. 9 Sep 2023Filings record

    Registered new securities for sale (S-1) (dated 8 Sep 2023)

  37. 29 Aug 2023Filings record

    Registered new securities for sale (S-1)

  38. 4 Aug 2023Filings record

    Delisting notice or listing transfer

  39. 28 Jul 2023Filings record

    Delisting notice or listing transfer

  40. 23 Jun 2023Insiders record

    Dudley Robert Michael (Chief Executive Officer) bought 18,607 shares of RNAZ ($48,648) (dated 22 Jun 2023)

Showing the newest 40 of 68 entries; narrow the window or the kind of data to see older ones.

Not listed: 75 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001829635
Ticker
RNAZ
Domain
transcodetherapeutics.com
Hq location
MA|BOSTON|02109 (1 unverified)
Name
TransCode Therapeutics, Inc.
Uei
M4SWK8BE2J85
  • SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)117 records26 Feb 2021 to 16 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)321 data points31 Dec 2019 to 12 Nov 2026
  • SEC Form 4 insider transactions8 records, 24 data points1 Jun 2022 to 2 Oct 2023
  • FINRA short interest (twice monthly)380 data points15 Jul 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2698 data points9 Jul 2021 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 21 data points16 Apr 2021 to 19 Jun 2025